Clone-Specific Drug Delivery Systems: Targeted Approaches and Future Clinical Applications

Year : 2025 | Volume : 12 | Issue : 02 | Page : 21-29
    By

    Suryakant Kumar,

  • Kamalesh Mistry,

  • Md. Zulphakar Ali,

  • Md. Aftab Alam,

  • Noorul Huda,

  • Neha Nahid,

  1. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  2. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  3. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  4. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  5. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  6. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_197621’);});Edit Abstract & Keyword

Clone-specific drug delivery systems represent a transformative frontier in personalized medicine, addressing the longstanding challenge of clonal heterogeneity within diseases such as cancer, infectious diseases, and autoimmune disorders. Traditional drug delivery platforms often fail to discriminate between pathogenic and healthy cells, leading to systemic toxicity and reduced therapeutic efficacy. In contrast, clone-specific systems aim to selectively target and eliminate disease-driving cellular clones based on unique molecular signatures, thereby improving treatment outcomes and minimizing adverse effects. These approaches leverage advanced technologies such as single-cell RNA sequencing, multi-omics profiling, CRISPR-based gene modulation, and ligand-directed nanocarriers to identify and selectively engage pathogenic clones. Innovations in polymeric nanoparticles, exosome-based delivery platforms, and bioengineered liposomes have enabled the design of smart, responsive delivery systems that release therapeutic payloads in a spatially and temporally controlled manner. Clone-specific targeting holds promise in oncology, where subclonal tumor evolution contributes to therapeutic resistance and disease relapse. Similarly, persistent clonal populations in infectious diseases and autoreactive immune cells in autoimmune disorders present critical targets for these next-generation therapies. The integration of artificial intelligence and big data analytics further enhances the identification and mapping of disease-relevant clones, allowing for real-time therapeutic modulation. Despite these advancements, several challenges remain, including off-target effects, scalability, regulatory approval, and ethical concerns. Nevertheless, ongoing preclinical and clinical studies underscore the translational potential of clone-specific drug delivery systems as a cornerstone of precision medicine.

Keywords: Clone-specific drug delivery, targeted therapy, clonal heterogeneity, nanoparticles, single-cell sequencing, CRISPR, precision medicine, smart drug delivery, personalized therapeutics, exosome-based therapy

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

How to cite this article:
Suryakant Kumar, Kamalesh Mistry, Md. Zulphakar Ali, Md. Aftab Alam, Noorul Huda, Neha Nahid. Clone-Specific Drug Delivery Systems: Targeted Approaches and Future Clinical Applications. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):21-29.
How to cite this URL:
Suryakant Kumar, Kamalesh Mistry, Md. Zulphakar Ali, Md. Aftab Alam, Noorul Huda, Neha Nahid. Clone-Specific Drug Delivery Systems: Targeted Approaches and Future Clinical Applications. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):21-29. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_197621’);});Edit

References

  1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.
  2. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release. 2011;153(3):198–205.
  3. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51.
  4. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–98.
  5. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.
  6. Barenholz Y. Doxil® the first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160(2):117–34.
  7. Zhang Y, Zhang RX, Wang Y, Fu CY, Chen J. Ligand-based targeted therapy: Molecular basis, design strategies and recent progress. J Drug Target. 2020;28(4):283–301.
  8. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286–98.
  9. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
  10. Ramasamy T, Ruttala HB, Chitrapriya N, Poudel BK, Youn YS, Kim JO. Engineered nanocarriers for improved drug delivery. J Control Release. 2017;263:153–70.
  11. Wang J, Wang Y, Xiong H, Li M, Li J. Aptamer-conjugated nanocarriers for targeted cancer therapy. Curr Med Chem. 2011;18(25):4165–74.
  12. Torchilin VP. Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;(197):3–53.
  13. Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL. Nanocarriers for precision delivery of drugs and nucleic acids. J Control Release. 2019;313:147–59.
  14. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev. 2013;65(1):104–20.
  15. Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical translation of nanomedicine. Chem Rev. 2015;115(19):11147–90.
  16. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale. 2012;4(2):330–42.
  17. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–63.
  18. He C, Lu JM, Lin WY, Jiang Z, Xia Y, Li D, et al. Nanomedicine applications of protein–polymer conjugates. J Control Release. 2016;240:67–81.
  19. He H, Liu L, Morin EE, Liu M, Schwendeman A. Mechanisms of injectable PLGA drug delivery systems for cancer therapy. Adv Drug Deliv Rev. 2020;159:264–83.
  20. Zhong Y, Goltsche K, Cheng L, Xie F, Meng F, Deng C, et al. Long-circulating, biodegradable polymeric nanoparticles for targeted drug delivery in cancer therapy. Chem Commun. 2014;50(85):12873–6.
  21. Mullard A. FDA approves landmark CAR-T therapy. Nat Rev Drug Discov. 2017;16(10):669.
  22. Ledford H. CRISPR treatment inserted directly into the body for first time. Nature. 2020;579(7797):185.
  23. Hynes RO. The extracellular matrix: Not just pretty fibrils. Science. 2009;326(5957):1216–9.
  24. Liu Z, Zhang L, Chen Y, Wang Q. Overcoming barriers for nanocarrier-based tumor targeting. Chem Soc Rev. 2020;49(2):227–48.
  25. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90–9.
  26. Riehle RD, Cornea V, Sullenger BA. Harnessing aptamers to image and treat cancer. Pharmacol Ther. 2018;181:126–38.
  27. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically‐based pharmacokinetic modelling in monoclonal antibody drug development. Clin Pharmacokinet. 2017;56(6):591–609.
  28. Ravi K, Kumar VR, Rathi S, Singh S, Patel B, Singh S, et al. A Comprehensive Review on Ulcer and Their Treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 21;39:e20230006. doi: 10.62958/j.cjap.2023.006. PMID: 38755116.
  29. Singh V, Arora S, Akram W, Alam S, Kumari L, Kumar N, et al. Involvement of molecular mechanism and biological activities of Pemirolast: A therapeutic review. New Emirates Med J. 2024;5:e02506882308410. https://doi.org/10.2174/0102506882308410240607053814
  30. Rajput DS, Gupta N, Singh S, Sharma B. A comprehensive review: personalized medicine for rare disease cancer treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 23;39:e20230008. doi: 10.62958/j.cjap.2023.008. PMID: 38830754.
  31. Singh S, Chaurasia A, Rajput DS, Gupta N. Mucoadhesive drug delivery system and there future prospective: are a promising approach for effective treatment? Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 20;39:e20230005. doi: 10.62958/j.cjap.2023.005. PMID: 38751344.
  32. Kumar S, Saha S, Sharma B, Singh S, Shukla P, Mukherjee S, et al. The role of resveratrol in Alzheimer’s disease: A comprehensive review of current research. Curr Funct Foods. 2023;2(2):e121223224364. https://doi.org/10.2174/0126668629269244231127071411
  33. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, et al. Recent innovations and future perspectives in transferosomes for transdermal drug delivery in therapeutic and pharmacological applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
  34. Vaghela MC, Rathi S, Shirole RL, Verma J, Shaheen, Panigrahi S, et al. Leveraging AI and machine learning in six-sigma documentation for pharmaceutical quality assurance. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jul 18;40:e20240005. doi: 10.62958/j.cjap.2024.005. PMID: 39019923.
  35. Singh S, Chaurasia A, Rajput DS, Gupta N. An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. Afr J Biol Sci (South Afr). 2024;6(5):522–41. https://doi.org/10.33472/AFJBS.6.5.2024.522-541
  36. Ravikkumar VR, Patel BD, Rathi S, Parthiban S, Upadhye MC, Shah AM, Rehan SSA, Samanta S, Singh S. Formulation and Evaluation of Drumstick Leaves Tablet as An Immunomodulator. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 21;40:e20240004. doi: 10.62958/j.cjap.2024.004. PMID: 38902996.
  37. Dewangan HK, Singh S, Mishra R, Dubey RK. A review on application of nanoadjuvant as delivery system. Int J Appl Pharm. 2020;12(4):24–33.
  38. Singh S, Chaurasia A, Gupta N, Rajput DS. Effect of formulation parameters on enalapril maleate mucoadhesive buccal tablet using quality by design (QbD) approach. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 27;40:e20240003. doi: 10.62958/j.cjap.2024.003. PMID: 38925868.
  39. Patel SK, Prathyusha S, Kasturi M, Godse KC, Singh R, Rathi S, et al. Optimizing irbesartan fast dissolving tablets using natural polysaccharides for enhanced drug delivery and patient compliance. Int Res J Multidiscip Scope (IRJMS). 2025;6(1):1181–90. https://doi.org/10.47857/
    2025.v06i01.02542
  40. Koo H, Huh MS, Ryu JH, Lee DE, Sun IC, Choi K, et al. Nanoprobes for biomedical imaging in cancer. Chem Soc Rev. 2011;40(7):2653–74.
  41. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405.
  42. Gill S, June CH. Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263(1):68–89.
  43. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
  44. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: Prospects and challenges. Nat Med. 2015;21(2):121–31.
  45. Shen Y, Jin E, Zhang B, Liu L, Zhang Q. Smart stimuli-responsive nanocarriers for drug delivery. Curr Pharm Des. 2019;25(7):752–65.
  46. Wang F, Chen L, Zhang R, Chen Z. A review on nanocarriers for the delivery of small molecule drugs in cancer therapy. Chin Chem Lett. 2020;31(3):641–8.
Regular Issue Subscription Original Research
Volume 12
Issue 02
Received 10/04/2025
Accepted 12/04/2025
Published 12/07/2025
Publication Time 93 Days
69

[first_name] [last_name]

My IP

PlumX Metrics